Abstracts tagged "BLyS and Lupus"

Abstract Number: 2586 • 2017 ACR/ARHP Annual Meeting
Exposure-Response Modelling and Exposure-Safety Modelling Analyses in Two Phase II Studies of Atacicept in SLE
Orestis Papasouliotis¹, Oezkan Yalkinoglu¹, Cristina Vazquez-Mateo², Stephen Wax³, Amy H. Kao², Peter Chang³, Patricia Fleuranceau-morel² and Lisa Mahnke², ¹Merck KGaA, Darmstadt, Germany, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA
Background/Purpose: Atacicept targets the B-cell stimulating factors BLyS and APRIL, and has been shown to reduce SLE disease activity. Our analyses evaluated the exposure-response and…
Abstract Number: L6 • 2012 ACR/ARHP Annual Meeting
Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus
Richard A. Furie¹, Morton A. Scheinberg², Gustavo Leon³, Edgar B. Ramiterre⁴, Matthew Thomas⁵, Renee S. Martin⁶ and Michelle Petri⁷, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ³Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁴Brokenshire Memorial Hospital, Davao City, Philippines, ⁵Health and Research Centre, Trivandrum, Kerala, India, ⁶Anthera Pharmaceuticals Inc, Hayward, CA, ⁷Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: To evaluate the efficacy, safety, and tolerability of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of soluble- and membrane-bound B-cell activating factor (BAFF), in patients…